- Home
- KPLT vs INKT Comparison
KPLT vs INKT Comparison
Compare KPLT & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPLT
- INKT
- Stock Information
- Founded
- KPLT 2012
- INKT 2017
- Country
- KPLT United States
- INKT United States
- Employees
- KPLT N/A
- INKT N/A
- Industry
- KPLT Diversified Commercial Services
- INKT Medicinal Chemicals and Botanical Products
- Sector
- KPLT Consumer Discretionary
- INKT Health Care
- Exchange
- KPLT Nasdaq
- INKT Nasdaq
- Market Cap
- KPLT 35.6M
- INKT 31.2M
- IPO Year
- KPLT N/A
- INKT 2021
- Fundamental
- Price
- KPLT $6.71
- INKT $7.50
- Analyst Decision
- KPLT Hold
- INKT Strong Buy
- Analyst Count
- KPLT 2
- INKT 2
- Target Price
- KPLT $12.00
- INKT $37.50
- AVG Volume (30 Days)
- KPLT 34.5K
- INKT 3.7K
- Earning Date
- KPLT 05-15-2025
- INKT 05-15-2025
- Dividend Yield
- KPLT N/A
- INKT N/A
- EPS Growth
- KPLT N/A
- INKT N/A
- EPS
- KPLT N/A
- INKT N/A
- Revenue
- KPLT $247,194,000.00
- INKT N/A
- Revenue This Year
- KPLT $20.12
- INKT N/A
- Revenue Next Year
- KPLT $13.19
- INKT N/A
- P/E Ratio
- KPLT N/A
- INKT N/A
- Revenue Growth
- KPLT 11.56
- INKT N/A
- 52 Week Low
- KPLT $5.08
- INKT $4.56
- 52 Week High
- KPLT $23.54
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- KPLT 33.40
- INKT 48.04
- Support Level
- KPLT $6.80
- INKT $6.34
- Resistance Level
- KPLT $7.75
- INKT $7.76
- Average True Range (ATR)
- KPLT 0.50
- INKT 0.58
- MACD
- KPLT 0.09
- INKT 0.03
- Stochastic Oscillator
- KPLT 31.13
- INKT 69.46
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.